You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.
For Australian specific enquiries, please click here.
You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or information contained on the server or site which you will be accessing. The information contained might not comply with the Australian regulatory environment.
Amgen has built an organisation distinguished by world-class scientists with a talent for applying novel approaches to treat disease. Our R&D strategy aims to align and engage our talent, prioritise investments, and seize scientific opportunities.
With the union of technology and biotechnology, we are at a hinge moment in drug discovery and development. Amgen's scientific success is grounded in unique capabilities that include:
Insights from human data will help us improve understanding of disease predictions, identify new targets, as well as find the right patient populations for the next generation of first-in-class therapeutics.
At Amgen we believe greater understanding can be found by delving deeper into our DNA.
The huge growth of biological data and computational technologies are allowing scientists to perform a wide range of analysis in a much more rapid and cost-effective way than previously possible, even just 20 years prior.
Data science is also changing the way researchers can understand, diagnose, and track diseases for the next generation of first-in-class therapeutics.
deCODE, our Icelandic subsidiary, is leading the way in collection and analysis of genomics and to find meaningful insights by applying a multi-omics approach.
The use of omics in drug development allows us to deliver transformative therapies.
We are investing in the power of artificial intelligence (AI), data science and other technologies to create the next generation of medicines that will bring the most value to patients.
The sophistication of drug discovery has evolved.
Generative Biology and the convergence of machine learning, AI technology and biology reimagines the protein drug discovery process.
Amgen is exploring this new wave of innovation to predict protein structures and reduce discovery timelines with the goal of increasing success rates.
Leveraging biology insights, AI and machine learning we are moving from the idea of a protein to a medicine.
Multispecific medicines have the potential to radically alter our concept of how drugs work and pave the way for new therapies.
Conventional medicines are produced to target a protein and attach that protein to alter its activity.
Today, many diseases have proteins too big or too complex that are hard to tackle with conventional drugs.
This is evolving toward a new approach in drug design called multi specifics.
Multi Specifics use an induced proximity process to bring together a disease target and an effector.
It acts on that target, or it uses built in zip codes that deliver the drug to its site of action.
Multispecifics are shaping the future of medicine in the biopharmaceutical industry to fight against diseases considered untreatable.
They’re using the body’s natural biological mechanisms to reach targets which were considered out of reach previously.
We are innovating clinical trials in ways that are improving our understanding of the natural course of disease as well as our ability to predict patient responses to the new medicines in development.
Amgen is innovating new ways to get medicines to patients faster.
To achieve that, our R&D strategy in clinical trials is focused on leveraging innovative clinical trials design, real world data and digital technologies to accelerate drug development.
We are continuously working to achieve equitable access to clinical trials by improving the diversity of participants in a study and ensuring they are more characteristic of a broader patient population.
Adaptive clinical trials allow continual learning as data is being collected, helping to find new solutions for those who are afflicted with the disease we seek to treat.
We are now evolving the way we think and run clinical trials applying new approaches in design and execution to improve efficiency and flexibility and to increase speed.
Explore our pipeline to see how we’re leveraging state-of-the-art science and molecular engineering in the pursuit of transformative medicines.